JP2012530118A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530118A5 JP2012530118A5 JP2012515552A JP2012515552A JP2012530118A5 JP 2012530118 A5 JP2012530118 A5 JP 2012530118A5 JP 2012515552 A JP2012515552 A JP 2012515552A JP 2012515552 A JP2012515552 A JP 2012515552A JP 2012530118 A5 JP2012530118 A5 JP 2012530118A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- sodium
- solvent
- pemirolast
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- KYIZZXKWRKKFSQ-UHFFFAOYSA-N sodium 9-methyl-3-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical class [Na+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 KYIZZXKWRKKFSQ-UHFFFAOYSA-N 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000008025 crystallization Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012296 anti-solvent Substances 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 claims 1
- 229960004439 pemirolast Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- -1 sodium alkoxide Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18734809P | 2009-06-16 | 2009-06-16 | |
| US18735509P | 2009-06-16 | 2009-06-16 | |
| US61/187,348 | 2009-06-16 | ||
| US61/187,355 | 2009-06-16 | ||
| PCT/GB2010/001168 WO2010146348A2 (en) | 2009-06-16 | 2010-06-15 | New crystalline form of pemirolast |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060587A Division JP2015120750A (ja) | 2009-06-16 | 2015-03-24 | ペミロラストの新しい結晶形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530118A JP2012530118A (ja) | 2012-11-29 |
| JP2012530118A5 true JP2012530118A5 (enExample) | 2013-07-25 |
| JP5722317B2 JP5722317B2 (ja) | 2015-05-20 |
Family
ID=43264726
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515552A Expired - Fee Related JP5722317B2 (ja) | 2009-06-16 | 2010-06-15 | ペミロラストの新しい結晶形 |
| JP2015060587A Pending JP2015120750A (ja) | 2009-06-16 | 2015-03-24 | ペミロラストの新しい結晶形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060587A Pending JP2015120750A (ja) | 2009-06-16 | 2015-03-24 | ペミロラストの新しい結晶形 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20120157415A1 (enExample) |
| EP (2) | EP2443120B1 (enExample) |
| JP (2) | JP5722317B2 (enExample) |
| KR (2) | KR20170049645A (enExample) |
| CN (1) | CN102596202B (enExample) |
| AR (1) | AR077915A1 (enExample) |
| AU (1) | AU2010261540B2 (enExample) |
| BR (1) | BRPI1015559A2 (enExample) |
| CA (1) | CA2765408A1 (enExample) |
| CY (1) | CY1118413T1 (enExample) |
| DK (1) | DK2443120T3 (enExample) |
| EA (1) | EA025865B1 (enExample) |
| ES (1) | ES2613059T3 (enExample) |
| HR (1) | HRP20170023T1 (enExample) |
| HU (1) | HUE032978T2 (enExample) |
| IL (1) | IL216670A (enExample) |
| LT (1) | LT2443120T (enExample) |
| ME (1) | ME02685B (enExample) |
| MX (1) | MX2011013676A (enExample) |
| NZ (1) | NZ596747A (enExample) |
| PL (1) | PL2443120T3 (enExample) |
| PT (1) | PT2443120T (enExample) |
| RS (1) | RS55558B1 (enExample) |
| SA (1) | SA114350792B1 (enExample) |
| SG (1) | SG176295A1 (enExample) |
| SI (1) | SI2443120T1 (enExample) |
| SM (2) | SMT201700085T1 (enExample) |
| TW (1) | TWI504599B (enExample) |
| UY (1) | UY32711A (enExample) |
| WO (2) | WO2010146348A2 (enExample) |
| ZA (1) | ZA201109045B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2780382A1 (en) * | 2009-11-13 | 2011-05-19 | Cardoz Ab | Pemirolast for the treatment of systemic low grade inflammation |
| EP3978002A1 (en) * | 2013-03-09 | 2022-04-06 | Chiesi Farmaceutici S.p.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| US20160243122A1 (en) | 2014-10-23 | 2016-08-25 | Rspr Pharma Ab | Use of pemirolast in the treatment of acute asthma |
| WO2016102941A1 (en) | 2014-12-22 | 2016-06-30 | Rspr Pharma Ab | New combination of pemirolast and montelukast |
| GB201518831D0 (en) | 2015-10-23 | 2015-12-09 | Rspr Pharma Ab | New use |
| AU2017340594B2 (en) * | 2016-10-03 | 2020-09-10 | Brivention Pharmaceutical (Shanghai) Inc. | Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| JP2504788B2 (ja) | 1987-11-10 | 1996-06-05 | 東京田辺製薬株式会社 | ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤 |
| JP2837449B2 (ja) * | 1989-08-11 | 1998-12-16 | 東京田辺製薬株式会社 | ピリド［１，２―ａ］ピリミジン誘導体の製造法 |
| ITMI20011764A1 (it) | 2001-08-10 | 2003-02-10 | Dinamite Dipharma Spa | Metodo per l'ottenimento del pemirolast ad elevata purezza |
| BRPI0615775B1 (pt) | 2005-09-16 | 2021-08-10 | Daiichi Sankyo Company, Limited | Processos para a produção de compostos derivados de diamida oticamente ativos |
| EA200900815A1 (ru) * | 2006-12-18 | 2009-12-30 | Кардос Аб | Новая комбинация, предназначенная для лечения воспалительных нарушений |
| US20100168137A1 (en) * | 2006-12-20 | 2010-07-01 | Johan Raud | Combination for use in the treatment of inflammatory disorders |
-
2010
- 2010-06-15 UY UY0001032711A patent/UY32711A/es not_active Application Discontinuation
- 2010-06-15 ME MEP-2017-8A patent/ME02685B/me unknown
- 2010-06-15 TW TW099119396A patent/TWI504599B/zh not_active IP Right Cessation
- 2010-06-15 WO PCT/GB2010/001168 patent/WO2010146348A2/en not_active Ceased
- 2010-06-15 CA CA2765408A patent/CA2765408A1/en not_active Abandoned
- 2010-06-15 HU HUE10732402A patent/HUE032978T2/hu unknown
- 2010-06-15 PL PL10732402T patent/PL2443120T3/pl unknown
- 2010-06-15 EA EA201200017A patent/EA025865B1/ru not_active IP Right Cessation
- 2010-06-15 KR KR1020177012036A patent/KR20170049645A/ko not_active Ceased
- 2010-06-15 MX MX2011013676A patent/MX2011013676A/es active IP Right Grant
- 2010-06-15 RS RS20170003A patent/RS55558B1/sr unknown
- 2010-06-15 SG SG2011088655A patent/SG176295A1/en unknown
- 2010-06-15 JP JP2012515552A patent/JP5722317B2/ja not_active Expired - Fee Related
- 2010-06-15 HR HRP20170023TT patent/HRP20170023T1/hr unknown
- 2010-06-15 EP EP10732402.2A patent/EP2443120B1/en active Active
- 2010-06-15 KR KR1020127001227A patent/KR20120032530A/ko not_active Ceased
- 2010-06-15 US US13/378,787 patent/US20120157415A1/en not_active Abandoned
- 2010-06-15 NZ NZ596747A patent/NZ596747A/en not_active IP Right Cessation
- 2010-06-15 BR BRPI1015559A patent/BRPI1015559A2/pt not_active IP Right Cessation
- 2010-06-15 WO PCT/GB2010/001159 patent/WO2010146341A2/en not_active Ceased
- 2010-06-15 SM SM20170085T patent/SMT201700085T1/it unknown
- 2010-06-15 DK DK10732402.2T patent/DK2443120T3/en active
- 2010-06-15 SI SI201031380A patent/SI2443120T1/sl unknown
- 2010-06-15 LT LTEP10732402.2T patent/LT2443120T/lt unknown
- 2010-06-15 ES ES10732402.2T patent/ES2613059T3/es active Active
- 2010-06-15 PT PT107324022T patent/PT2443120T/pt unknown
- 2010-06-15 EP EP16194237.0A patent/EP3141549A1/en not_active Withdrawn
- 2010-06-15 CN CN201080026883.3A patent/CN102596202B/zh not_active Expired - Fee Related
- 2010-06-15 AU AU2010261540A patent/AU2010261540B2/en not_active Ceased
- 2010-06-16 SA SA114350792A patent/SA114350792B1/ar unknown
- 2010-06-16 AR ARP100102136A patent/AR077915A1/es unknown
-
2011
- 2011-11-29 IL IL216670A patent/IL216670A/en not_active IP Right Cessation
- 2011-12-08 ZA ZA2011/09045A patent/ZA201109045B/en unknown
-
2014
- 2014-05-12 US US14/274,951 patent/US9006431B2/en not_active Expired - Fee Related
-
2015
- 2015-03-24 JP JP2015060587A patent/JP2015120750A/ja active Pending
-
2016
- 2016-12-28 US US15/392,497 patent/US20170202839A1/en not_active Abandoned
-
2017
- 2017-01-11 CY CY20171100039T patent/CY1118413T1/el unknown
- 2017-02-08 SM SM201700085T patent/SMT201700085B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014162794A5 (enExample) | ||
| JP2012500805A5 (enExample) | ||
| JP2012176975A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| HRP20210194T1 (hr) | Nove soli i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja | |
| JP2011528658A5 (enExample) | ||
| JP2016535031A5 (enExample) | ||
| JP2013237682A5 (enExample) | ||
| SI2956452T1 (en) | Heterocyclic amides as kinase inhibitors | |
| RU2015143643A (ru) | Соль омекамтива мекарбила и способ ее получения | |
| JP2015509973A5 (enExample) | ||
| NZ625087A (en) | Combination formulation of two antiviral compounds | |
| JP2017522276A5 (enExample) | ||
| JP2013049690A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2014501282A5 (enExample) | ||
| JP2014169319A5 (enExample) | ||
| JP2010516681A5 (enExample) | ||
| JP2014512451A5 (enExample) | ||
| JP2015500331A5 (enExample) | ||
| HRP20170540T1 (hr) | Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja | |
| JP2015516425A5 (enExample) | ||
| JP2013541592A5 (enExample) | ||
| JP2013538849A5 (enExample) | ||
| JP2013503134A5 (enExample) |